Skip to main content
TipRanks
Go Ultimate75% OFF

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Stock Price & Analysis

1 Followers

2315 Stock Chart & Stats

HK$39.98-HK$1.42(-3.43%)
At close: 4:00 PM GMT+8
HK$40HK$60HK$80Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2Nov 16
Day’s Range
HKD 39.64 - HKD 41.40
52-Week Range
HKD 24.80 - HKD 80.65
Previous Close
HKD 41.40
Volume
N/A
Average Volume (3M)
2.36M
Market Cap
HKD 17.77B
Enterprise Value
HKD 20.54B
Total Cash (Recent Filing)
HKD 1.04B
Total Debt (Recent Filing)
HKD 869.00M
Price to Earnings (P/E)
39.9
Beta
0.71
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Scale And Margins

The company has expanded revenue substantially over several years while preserving high gross margins, indicating attractive economics across its research, technology, and antibody-related activities. This combination can support reinvestment in platforms and drug candidates while strengthening operating leverage as the business scales.

Profitability Inflection

The shift from losses through 2023 to positive and expanding profitability in 2024–2025 is a meaningful improvement in business performance. If execution continues, the stronger earnings base can improve internal funding capacity, support research investment, and provide greater resilience than the prior loss-making model.

Improved Cash Generation And Leverage

Positive operating and free cash flow provide evidence that recent earnings are translating into financial resources, rather than remaining solely accounting-based. Combined with lower debt-to-equity, this improves funding flexibility for platform development and partnerships and reduces balance-sheet pressure over the medium term.

Bears Say

Profitability Durability

Although profitability improved sharply, the recent history of deep losses shows that earnings have not yet been proven across a full operating cycle. Maintaining positive margins will require continued execution in research services, collaborations, and antibody programs, making the durability of the inflection a material risk.

Free Cash Flow Volatility

The company is currently generating positive cash, but the year-over-year decline in 2025 and earlier periods of sizable outflows indicate that cash conversion can fluctuate materially. This variability may constrain the consistency of internally funded investment if operating performance weakens or research spending rises.

Capital Structure Volatility

Improved leverage is constructive, but volatility in capital structure and equity levels adds uncertainty to the stability of the financial base. If profitability weakens, changing equity or financing needs could reduce flexibility and make it harder to sustain research investment without increasing balance-sheet risk.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H News

2315 FAQ

What was Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price range in the past 12 months?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H lowest stock price was HK$24.80 and its highest was HK$80.65 in the past 12 months.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap is HK$17.77B.
When is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s earnings last quarter?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H released its earnings results on Oct 29, 2026. The company reported HK$0.188 earnings per share for the quarter.
Is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pay dividends?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H does not currently pay dividends.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H have?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding.
What happened to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price movement after its last earnings report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H reported an EPS of HK$0.188 in its last earnings report. Following the earnings report the stock price went down -2.189%.
Which hedge fund is a major shareholder of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2315
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology